Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-12-12
2006-12-12
Helms, Larry R. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C436S063000, C436S064000, C436S501000, C436S503000, C436S504000, C436S505000, C436S518000
Reexamination Certificate
active
07148016
ABSTRACT:
Disclosed are immunoassay methods for the diagnosis/prognosis of diseases and disease susceptibility traits associated with gene mutations that cause protein truncation or allelic loss. The levels of one or more targeted wild-type proteins expressed by a subject gene or genes are immunologically quantitated in biological samples. Results indicating that a targeted wild-type protein is not present in an assayed sample, or that approximately 50% of the normal amount of such a wild-type protein is present in an assayed sample are considered to be positive for a mutation in one or both alleles of a subject gene, and correlated with the disease or the disease susceptibility trait associated with that mutation or mutations. Normal cells, particularly normal peripheral blood lymphocytes, are preferred biological samples.
REFERENCES:
patent: 5328826 (1994-07-01), Nozawa et al.
patent: 5569608 (1996-10-01), Sommer
patent: 5591826 (1997-01-01), de la Chapelle et al.
patent: 5602243 (1997-02-01), Vogelstein
patent: 5650281 (1997-07-01), Vogelstein
patent: 5709998 (1998-01-01), Kinzler et al.
patent: 5837443 (1998-11-01), de la Chapelle et al.
patent: 5866323 (1999-02-01), Markowitz et al.
patent: 5922855 (1999-07-01), Liskay et al.
patent: 6048701 (2000-04-01), Kinzler et al.
patent: 6124104 (2000-09-01), Tavtigian et al.
patent: 6165713 (2000-12-01), Liskay et al.
patent: 6191268 (2001-02-01), Liskay et al.
patent: 6413727 (2002-07-01), Albertsen et al.
patent: 6538108 (2003-03-01), Liskay et al.
patent: 2003/0224463 (2003-12-01), Liskay et al.
patent: 0507852 (1998-04-01), None
patent: 9109964 (1991-07-01), None
patent: 9514085 (1995-05-01), None
patent: 9516793 (1995-06-01), None
patent: WO 97/08341 (1997-03-01), None
Passlick, B. et al. Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small-cell lung cancer. J. Thoracic and Cardiovascular Surgery, 109(6): 1205-1211, 1995.
Bouffler, S.D. et al, Bristish Journal of Cancer, 2000, 83: 1291-1294.
Glendening, J. M. et al, Cancer Res. 55(23): 5531-5535, 1995.
Gill, S. et al., Clin. Cancer Res. 11(18):6466-6471, 2005.
Boehringer-Mannheim, GmBH, “New Detection Methods for the Protein Truncation Test, Nonradioactive (PTT),”Biochemica, 3: 21 (1997).
Boehringer-Mannheim, “More New Products to Meet Your Changing Needs,”Biochemica, 1:
Boehringer Mannheim, “Protein Truncation Test, nonradioactive,” test kit pamplet Cat. No. 1 888 439 (1997) accompanied by advertisement therefor.
Boman, B. M., “Biologic functions of the genes responsible for familial cancer,”Current Opinion in Oncology, 6: 90-95 (1994).
Boman et al., “Radioimmunoassay of the APC Gene Product Using Antibodies against Its Middle and Carboxyl Regions,”Biochem. Biophys. Res. Comm., 206(3): 909-915 (1995).
Charbonnier et al., “Alernative Splicing of MLH1 Messenger RNA in Human Normal Cells,”Cancer Research, 55: 1839-1841 (May 1, 1995).
Chop et al., “Immunodetection of the Presence or Absence of Full-Length APC Gene Product in Human Colonic Tissues,”Anticancer Res., 15: 991-998 (1995).
Drummond et al., “Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line,”The Journal of Biological Chemistry, 271(33): 19645-19648 (1996).
Hemminki et al., “Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer,”Nature Genetics, 8: 405-410 (Dec. 1994).
Hogervorst, F.B.L., “The Protein Truncation Test (PTT),”Promega Notes Magazine, 62: 7-14 (1997).
Froggatt et al., “Mutation screening of MSH2 and MLH1 mRNA in hereditary non-polyposis colon cancer syndrome,”J. Med. Genet., 33: 726-730 (1996).
Kolodner and Alani, “Mismatch repair and cancer susceptibility,”Current Opinion in Biotechnology, 5:585-594 (1994).
Levy et al., “Inactivation of Both APC Alleles in Human and Mouse Tumors,”Cancer Res., 54: 5953-5958 (Nov. 15, 1994).
Lynch et al., “Hereditary Nonpolyposis Colorectal Cancer—Lynch Syndromes I and II,”Gastroenterology Clinics of North America, 17(4): 679-712 (Dec. 1988).
Lynch and Lynch, “25 Years of HNPCC,”Anticancer Research, 14: 1617-1624 (1994).
Miret et al., “Characterization of a DNA Mismatch-binding Activity in Yeast Extracts,”The Journal of Biological Chemistry, 268(5): 3507-3513 (1993).
Roest et al., “Protein Truncation Test (PTT) to Rapidly Screen the DMD Gene for Translation Terminating Mutations,”Neuromusc. Disord, 3(5/6): 391-394 (1993).
Smith et al., “The APC gene product in normal and tumor cells,”PNAS(USA) 90: 2846-2850 (Apr. 1993).
Powell et al., “Molecular Diagnosis of Familial Adenomatous Polyposis,”The New England Journal of Medicine, 329(27): 1982-1987 (Dec. 30, 1993).
Stankovic et al., “ATM Mutations and Phenotypes in Ataxia-Telangiectasia Families in the British Isles: Expression of Mutant ATM and the Risk of Leukemia, Lymphoma, and Breast Cancer,”Am. J. Hum. Genet., 62: 334-345 (1998).
Tannergard et al., “Mutation Screening in the hMLH1 Gene in Swedish Hereditary Nonpolyposis Colon Cancer Families,”Cancer Research, 55: 6092-6096 (Dec. 15, 1995).
van der Luijt et al., “Rapid Detection of Translation-Terminating Mutations at theAdenomatous Polyposis Coli(APC) Gene by Direct Protein Truncation Test,”Genomics, 20: 1-4 (1994).
Wagner et al., “Mutation detection using immobilized mismatch binding protein (MutS),”Nucleic Acids Research, 23(19): 3944-3948 (1995).
Wei et al., “Reduced Expression of Mismatch Repair Genes Measured by Mutliplex Reverse Transcription-Polymerase Chain Reaction in Human Gliomas,”Cancer Research, 57(9): 1673-1677 (1997).
Fields et al., “Immunoassay for wild-type protein in lymphocytes predicts germline mutations in patients at risk for hereditary colorectal cancer,”J. Lab Clin. Med., 143(1): 59-66 (Jan. 2004).
Shigeta et al., “Defective Control of Apoptosis and Mitotic Spindle Checkpoint in Heterozygous Carriers of ATM Mutations,”Cancer Research, 59: 2602-2607 (Jun. 1, 1999).
Marchuk , D.A., “Genetic abnormalities in hereditary hemorrhagic telanglectasia,”Current Opinion in Hematology, 5: 332-338 (1998).
Pece et al., “Mutant Endoglin in Hereditary Hemorrhagic Telangiectasia Type 1 Is Transiently Expressed Intracellularly and Is Not a Deominant Negative,”J. Clin. Invest., 100(10): 2568-2579 (Nov. 1997).
Meyers et al., “Cell Cycle Regulation of the Human DNA Mismatch Repair Genes hMSH2, hMLH1, and hPMS2,”Cancer Research, 57: 206-208 (Jan. 15, 1997).
Veitia, R.A., “Exploring the etiology/of haploinsufficiency,”BioEssays, 24: 175-184 (2002).
Berg et al., “The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangietasia type 2,”Am. J. Hum. Genet., 61(1): 60-67 (Jul. 1997).
Chin et al., “The INK4a/ARF tumor Suppressor: one gene-two products—two pathways,”Trends Biochem. Sci., 23(8): 291-296 (Aug. 1998).
Nagy et la., “Lack of mutation of the folliculin gene in sporadic chromophobe renal cell carcinoma and renal oncocytoma,”Int J. Cancer, 109(3): 472-475 (Apr. 10, 2004).
Gruis et al., “Homozygotes from CDKN2 (p16) germline mutation in Dutch familial melanoma Kindreds,”Nat. Genet., 10(3) 351-353 (Jul. 1995).
Boddrich et al., “Reduced Neurofibromin Content but Normal Gap Activity in a Patient with Neurofibromatosis Type 1 Caused by a Five Base Pair Duplication in Exon 12B of the NF1 Gene,”Biochemical and Biophysical Research Communications, 214(3): 895-904 (Sep. 25, 1995).
Czech et al., “Proteolytical processing of mutated human amyloid precursor protein in transgenic mice,”Molecular Brain Research, 47: 108-116 (1997).
Mortola and Nasto, “Brown adipose tissue an
CA*TX Inc.
Harland Joan C.
Helms Larry R.
Holleran Anne L.
Lauder Leona L.
LandOfFree
Immunoassays to detect diseases or disease susceptibility... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunoassays to detect diseases or disease susceptibility..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoassays to detect diseases or disease susceptibility... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3656091